Introduction: In the western hemisphere,
[OCT]) has been employed [7, 8] . Such classification categorizes CNV lesions as type 1 (CNV beneath the retinal pigment epithelium
[RPE]), type 2 (CNV that has penetrated the RPE/Bruch membrane complex and is present in the subretinal layer above the RPE), and type 3 (intraretinal neovascularization formerly the treatment of neovascular AMD [18] . On November 18, 2011, the FDA approved VEGF Trap-Eye for the treatment of patients with neovascular AMD. The recommended dosage of VEGF Trap-Eye injection is 2 mg given every 4 weeks for the first 12 weeks, followed by 2 mg every 8 weeks [19] .
Surgery
The Submacular Surgery Trial (SST), a large, randomized clinical trial, has not established any significant benefit of surgery in patients with AMD [20, 21] . Surgical therapies, including submacular surgery and macular translocation, are currently recommended only in neovascular AMD cases where anti-VEGF therapy has not been shown to be effective [22] . 
Anti-VEGF Therapy
In December 2004, the FDA approved intravitreal (IVT) administration of 0.3 mg pegaptanib sodium every 6 weeks for the treatment of all forms of neovascular AMD [17] . Two years later, in June 2006, monthly IVT injections of ranibizumab (RBZ) 0.5 mg were approved for [26] Monoclonal IgG antibody fragment (Fab) [31] Monoclonal IgG antibody [32] RNA aptamer-secreted protein [33] 
Mechanism of action
Binds to all forms of VEGF-A, VEGF-B, and PlGF [26, 27] Binds to all forms of VEGF-A [31] Binds to all forms of VEGF-A [30] Binds to VEGF-A 165 [33] Half-life in vitreous humor 4.79 days (in rabbits) [29] 2.88-2.89 days for 0.5 mg (in rabbits) [31, 34] 2.63 and 3.9 days for 0.5 mg and 2 mg (in monkeys) [35] 4.32-6.61 days for 1.25 mg (in rabbits) [32] 6.7 days for 1.25 mg (in humans) [30] 10 ± 4 days (in humans) [33, 36] FDA approval Neovascular AMD [28] Neovascular AMD, macular edema secondary to retinal vein occlusion [18, 37] Metastatic renal and colorectal cancers; glioblastoma; non-small cell lung cancer [38] Off-label use for AMD Neovascular AMD [17] AMD RTP801i-14) [23, 24] .
The class of drugs that has shown to be most effective against angiogenesis is the VEGF antagonists [25] . The efficacy of these agents has been studied extensively in several phase 3 trials resulting in a paradigm shift in the management of neovascular AMD. A summary of the properties of anti-VEGFs currently employed in managing patients with neovascular AMD is presented in Table 1 [17, 18, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] .
THE VEFG PATHWAY
V E G F i s a n i m p o r t a n t m e d i a t o r o f neovascularization. It also increases vessel permeability, and is about 50,000 times more potent than histamine in inducing vascular leakage [39] . The mammalian VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF (placental growth factor). VEGF-A 165 is the most abundantly expressed and biologically active form in the human body [40] . polysorbate 20, and 5% sucrose, pH 6.2) and needs to be stored at 2-8°C (36-46°F) [37] .
Dosing
The recommended dosage of VEGF Trap-Eye for neovascular AMD, based on the approval by the FDA, is 2 mg given every 4 weeks for the first 12 weeks, followed by 2 mg every 8 weeks. VEGF Trap-Eye may be dosed as frequently as 2 mg every 4 weeks [19, 68] . In the PIER study, monthly injections were given for 3 months followed by quarterly injections.
CLINICAL TRIALS WITH ANTI-VEGF PHARMACOLOGIC AGENTS AND IMPLICATIONS FOR NEOVASCULAR AMD THERAPY
However, it failed to show the same benefits that were seen when monthly injections were given in the MARINA and ANCHOR trials [76, 77] . On the other hand, the PrONTO study established 
VEGF TRAP-EYE AND OTHER RETINAL VASCULAR DISEASES
In addition to neovascular AMD, VEGF Trap-Eye is also being studied as a potential therapy for DME and CRVO.
In an exploratory study of five patients, Do and GALILEO studies, respectively [57, 94] . 
